Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07163091Not ApplicableRecruiting

Bracing After Ankle Fracture

Role: collaborator

NCT07485140Recruiting

Prevention of Preeclampsia in Denmark: A National Implementation Study

Role: collaborator

NCT07361952Not ApplicableRecruiting

Oral Versus Intravenous Fluid Therapy in the Emergency Department

Role: collaborator

NCT04688788Phase 3Active Not Recruiting

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Role: collaborator

All 4 trials loaded